Combination therapy using an agent or anti EGFR agents and specific inhibitors of igf-1r

摘要

It describes a combination of IGF-1R antagonists, such as a human antibody and an anti-proliferation drug. In the process of priority realization, the invention describes a combination of an antigen and IGF-1R, and an anti diffusion drug belonging to EFR inhibitor class, preferably Ertinib. In combination with the present invention, it is useful for the treatment of tumors, including medium tumors or tumors controlled by IGF-1R and / or EFR.